Targeting of protease activator receptor-2 (PAR-2) antagonist FSLLRY-NH2 as an asthma adjuvant therapy

Marinel Ocasio-Rivera, Frances Marin-Maldonado, MSb, Geraline Trossi-Torres, MSa, Angely Ortiz-Rosado, BSa, Valerie Rodríguez-Irizarry, BSb, Eric Rodriguez-Lopez, BSa, Sahayra Martínez, BSb, Sharilyn Almodóvar, PhDb, Edu Suarez-Martínez, PhDab,

Abstract
Asthma is a chronic inflammatory and multifactorial respiratory tract disease. It affects over 18 million adults and 6 million children in the USA with Puerto Ricans showing the highest prevalence (12%–19%). This airways illness can be triggered by an environmental stimulus such as grass pollen, fungi spores, cockroaches allergens, dust mites metabolic compounds, and importantly, by environmental proteases such as trypsin and tryptase. Because of the pivotal role of proteases in the onset of asthma pathophysiology, we focused this study on the serine Protease Activated Receptor-2 (PAR-2), a G-protein-coupled receptor widely expressed in cells across the respiratory tract. Herein, we measured the activation of PAR-2 on primary pulmonary bronchial/tracheal epithelial cells, human small airway epithelial cells, lung bronchial smooth muscle cells (with and without asthma). We tested human-derived eosinophils from 61 Puerto Rican participants (33 asthmatic and 28 non-asthmatic). As surrogate of PAR-2 activation or inhibition we used intracellular calcium mobilization assay. We hypothesized that following exposure of the PAR-2 agonist (AC264613), the studied human primary cell types will increase the mobilization of intracellular calcium levels. In contrast, we expected a decrease of the intracellular calcium levels upon exposure to a PAR-2 antagonist (FSLLRY-NH2). The Puerto Rican-derived eosinophils were analyzed for the proinflammatory markers MAPK/PI3K using flow cytometry (n=8). As expected, the PAR-2 agonist significantly increased the activation of PAR-2 on the bronchial/tracheal epithelial cells, bronchial smooth muscle cells and human small airway epithelial cells (P=0.01). The PAR-2 antagonist significantly decreased the intracellular calcium levels of these lung primary down to undetectable levels (P=0.01). Remarkably, the asthmatic-derived eosinophils showed a striking 300% increase of intracellular calcium mobilization suggesting a severe response to the PAR-2 agonist stimuli in asthmatics. In contrast, there were no significant changes between groups after adding the PAR-2 antagonist. Our outcomes revealed that PAR-2 antagonist effectively inhibited the studied primary cells, expecting to decrease the immune response of eosinophils. Most importantly, our results reveal a promising role for the PAR-2 antagonist in targeting bronchial/tracheal epithelial cells, human small airway epithelial cells and bronchial smooth muscle cells with the potential to oblige an asthma adjuvant therapy.

Abbreviations: AKT = Protein Kinase B, BSMC = Bronchial Smooth Muscle Cells, ERK1/2 = Extracellular Signal-Regulator Kinases, FDA = Food and Drug Administration, GPCR = G-Protein-Coupled Receptor, GPCRs = G-Protein-Coupled Receptors, HIPAA = Health Insurance Portability and Accountability Act, HSAEC = Human Small Airway Epithelial Cells, MAPK = Mitogen-Activated Protein Kinase, PAR-2 = Protease Activated Receptor-2, PARs = Protease Activated Receptors, PI3K = Phosphoinositide 3-Kinases.

Keywords: asthma, PAR-2, PAR-2 antagonist FSLLRY-NH2, protease activated receptor 2
1. Introduction
Asthma is a complex chronic inflammatory disease of the airways, varying in severity from occasional episodes of wheezing and shortness of breath to an irreversible, life-threatening lung obstructive disease. The CDC Behavioral Risk Factors Survey have consistently indicated that the lifetime prevalence of asthma in Puerto Rico (PR) is the highest in the USA and its territories with a 12% to 19% for the latest cohort.[1] Moreover, the Puerto Rican population shows inconsistent responses to pharmacological treatments compared to other ethnic groups.[1,2] As a multifactorial disease, many underlying causes of asthma remain unclear. Certainly, interactions occurring between genetic profiles and environmental factors contribute to its clinical manifestations. Importantly, the exposure to specific thresholds levels of allergen(s) has been identified for the severity and disparity of asthma in various populations worldwide, including grass pollen, fungi spores, cockroach allergens, and dust mites products. Moreover, enzymatic activity of environmental proteases such as trypsin and tryptase are associated with multiple pro-inflammatory and immunological responses characterized in the pathology of asthma.[3] For example, the Protease Activated Receptor-2 (PAR-2), a serine protease and autocaltyclic G-protein-coupled receptor (GPCR) is widely expressed in human cells across the respiratory tract including airway epithelial and smooth muscle cells, bronchial vascular and epithelial cells, type II pneumocytes, terminal bronchial epithelium, eosinophils, neutrophils, and mast cells.[4-9] All these cells play an important role in triggering, development, clinical manifestations, and severity of asthma. Trypsin and mast cell tryptase caused bronchoconstriction in animal models via the PAR-2 receptors.[10,11] Also, allergic mice exposed to trypsin showed increased expression of PAR-2 leading to eosinophil infiltration, airway hyper-reactivity, and inflammation considering PAR-2 a pro-inflammatory trigger.[10] However, studies of human PAR-2 at the cellular and molecular level are limited. Herein, we evaluated the potential of PAR-2 antagonism as a therapeutic cell specific target or adjuvant treatment for the health disparity of asthma. In fact, our findings provide insights on the contribution and role of PAR-2 agonist hypersensitivity on eosinophils derived from asthmatic participants. At the respiratory tract level, the outcome of the PAR-2 effectiveness, also open new projections for the development of a future delivery method such as an inhaled or aerosolized drug formulation. The PAR-2 antagonist will act reaching the respiratory cells, acting as potential treatment for the inhibition of the receptor signaling pathway by a reduction or blockage of the characteristic asthma-associated symptoms.

2. Methods
2.1. Cell culture
We seeded Bronchial/Tracheal Epithelial Cells (cat. PCS-300–014, ATCC, Virginia), Human Small Airway Epithelial Cells (HSAEC) (cat. PCS-301-010, ATCC, Virginia) and Bronchial Smooth Muscle Cells (BSMC) (cat. CC-2576, Lonza Clonetics, Switzerland) on T-75 flasks with the appropriate media and incubated under standard conditions (37°C, humidity 100% and 5% CO2) until reaching confluence of 90% to 95%. Then we trypsinized and seeded a total of 20,000 cells well in triplicates (96-well plate) of each respective cell type and per treatment, with subsequent use of the Fluo-4 Direct Calcium Assay Kit (cat. F10471, Invitrogen, California).

3. Participants
3.1. Patient confidentiality
This study was reviewed and approved by the Ponce Medical School Foundation Internal Review Board constituted by the following members: Simón E. Carlo, M.D., Chairman, Idhaliz Flores, Ph.D., Vanessa Rivera Amil, Ph.D., Victoria Michelen, M.D., Luisa Morales, Ph.D., Mary Rodríguez, Psy.D., Axel Ramos, PhD, Eliut Rivera, Ph.D., Mrs. Mardie Geiser, Ms. Elena Vélez, and Mrs. Migdalia Cruz. Following the established confidentiality protocols for the privileged participants information. Participant consent was given prior to start the studied tests, including the Health Insurance Portability and Accountability Act (HIPAA) enforcement. As a case-control study, we surveyed 216 candidates (August 2017 - March 2018) who were evaluated under the following criteria: Inclusion- a) All participants (asthmatics and non-asthmatics) must be Puerto Ricans residing in Puerto Rico; b) 3 generations of Puerto Ricans; c) Asthmatic participants must be physician-diagnosed; d) ages from 5 to 62 years; Exclusion- physician diagnosis for one of these illnesses: a) chronic bronchitis; b) pulmonary emphysema; c) congestive heart failure; d) cough secondary to drugs such as beta-blockers; e) chronic obstructive pulmonary disease (COPD); f) mastocytosis; g) parathyroid disease; h) recent allergic reaction; or i) any other chronic and inflammatory medical condition that restrict their daily activities. In the present study, we enrolled 67 qualifying participants; of these, we were able to isolate eosinophils from 61 subjects (33 asthmatic and 28 non-asthmatics). The male to female ratio was 1:1.77 (36% males and 64% females). The mean age was 30 ± 1.74 years.

3.2. Blood sampling and eosinophil purification
The eosinophil purification assay was performed using 20ml of K2EDTA-anticoagulated blood samples from participants within 24 hours after phlebotomy. We used the Human Eosinophil Enrichment Kit Stem (Cell Technologies #19256, Canada) and followed the manufacturer protocol as described. This system isolates the eosinophils from other granulocytes by negative selection, obtaining approximately one million cells per participant.

3.3. Calcium assay
We used the Fluo-4 Direct Calcium Assay Kit (Invitrogen #F10472, Massachusetts) to determine the intracellular calcium mobilization as well-established indicator of PAR-2 activation or inhibition of the 4 selected primary cell types. We seeded 20,000 cells/well in 96-well plates. We optimized the last incubation time from 2 hours (suggested) to 45 seconds after exposure to the treatments, PAR-2 agonist AC264613, and PAR-2 antagonist FSLLRY-NH2, due to the rapid kinetics of the PAR-2 activation (Fig. 1.) The intracellular calcium level was measured in triplicates and 3 repetitions by fluorescence at 485/20, 528/20 in relative fluorescence units (RFU), in a BioTek Synergy HT (Wisnouski, Vermont).

3.4. Flow cytometry
We used the Muse Cell Analyzer (7200150462, Austin, Texas) and the Muse P13K/ MAPK Dual Pathway Activation Kit (MCH200108, Texas) protocol to determine these markers on the human derived eosinophils was measured in triplicates and 2 repetitions.
3.5. Statistical analysis

Data analyses were performed using software SPSS v.26.0 and Graph Pad Prism 6. The significance level was established at \( P < .05 \). Clinical variables of cases and controls were compared by the \( X^2 \) test with 1 df (degree of freedom); we also used parametric and nonparametric tests as applicable.

4. Results

We used an intracellular calcium mobilization assay as indicator of the activation of PAR-2 associated signal transduction. Using the Fluo-4 Direct Calcium Assay Kit we optimized the acquisition parameters to our assay, in terms of incubation times prior to collect the data from the fluorometric readings and the PAR-2 agonist and antagonist concentrations (not shown). Based on our optimization experiments, the ideal experimental time for our cell type for PAR-2 activation and detection of intracellular calcium was 45 seconds (Fig. 1); the PAR-2 agonist and antagonist concentration ideal for our experimental conditions resulted at 10 \( \mu \)M for agonist and 0.5 \( \mu \)M for agonist.

Once we established the best parameters, we measured the intracellular calcium mobilization in the presence of each treatment. Our results showed a significant increase in intracellular calcium mobilization in Bronchial/Tracheal Epithelial Cells (\( P = .01 \)) (Fig. 2), Human Small Airway Epithelial Cells (\( P = .0024 \)) (Fig. 3), Bronchial Smooth Muscle Cells (\( P = .0001 \)) (Fig. 4) and Diseased Asthmatic Bronchial Sooth Muscle Cells (\( P = .01 \)) (Fig. 5) when exposed to the PAR-2 agonist. In contrast, PAR-2 expression was inhibited by showing significant decrease when we added the antagonist to these primary cells (Figs. 2–5).

Since asthma prevalence in Puerto Ricans is the highest in the Nation, we further explored the intracellular calcium mobilization in eosinophils derived from this population upon exposure to PAR-2 agonist and antagonist treatments by conducting a pilot case-control study with 33 asthmatic and 28 non-asthmatic participants. In the presence of the PAR-2 agonist, the eosinophils derived from the asthmatic group showed a significant 300% increase in PAR-2 activation when compared to the non-asthmatics (\( P < .0001 \)). Treatment with the PAR-2 antagonist, however, did not show significant decrease in the PAR-2 activation (Fig. 6).

To evaluate whether the observed significant increase of intracellular calcium in eosinophils was due to the asthma, we further stratified the cohort in allergic and non-allergic participants. Our results did not show significant activation (increase in intracellular calcium) nor inhibition (decrease of intracellular calcium) upon exposure to any of the treatments.
Only PAR-1 is being considered in Food and Drug Administration. The role of PAR-1, PAR-3, and PAR-4 has been extensively studied, whereas PAR-2 signal transduction is not entirely deciphered at the immune and in vivo level.

PAR-2 is activated by exogenous, environmental, or endogenous serine proteases such as trypsin and tryptase. PAR-2 is cleaved at the extracellular N-terminus domain, triggering a conformational change and directing the tethered ligand to bind to the second extracellular loop domain, which starts the signal transduction. Although the other members of this family can be agonized, PAR-2 is the only PAR that is strongly expressed in human respiratory airway epithelial cells, human bronchial vessels, human airway smooth muscle, type II pneumocytes, terminal bronchial epithelium, macrophages, eosinophils, neutrophils, and mast cells.

Importantly, all these are involved in the pathophysiology of asthma. Activated monocytes tested in vitro expressing PAR-2 produce proinflammatory cytokines, enhance airway reactivity, bronchoconstriction, and eosinophil infiltration in animal models.

Knight and colleagues reported one of the first PAR-2 case-control studies comparing asthmatics and non-asthmatic patients by studying biopsies with immunohistochemistry at the bronchial level, showing a significant overexpression of PAR-2 in asthmatics. On a separate study, Aubier et al., compared the immune cells profile collected from bronchoalveolar lavage fluid by using flow cytometry and measured the airway smooth muscle enlargement from asthmatic and non-asthmatic participants.

Still, a single clinical trial is active using PAR-2 agonist in congenital gastrointestinal disease, but none other clinical trial includes PAR-2 and asthma.

Therefore, herein we evaluated the effect of PAR-2 antagonist to decrease the activation of proinflammatory subsequent signal transduction in several relevant cells involved in the pathophysiology of asthma. We determined the effects of PAR-2 agonist AC264613 and PAR-2 antagonist FSLRRY-NH2 on human primary cells from different microenvironments within the respiratory tract, including bronchial/tracheal epithelial cells, small airway epithelial cells, bronchial smooth muscle cells, and patient-derived eosinophils from asthmatics and non-asthmatics groups.

Our choice of the PAR-2 agonist AC264613 is supported by literature indicating its affinity and specificity for PAR-2 without cross-reactivity to PAR-1, which structurally similar to PAR-2. The PAR-2 antagonist FSLRRY-NH2 was selected due to its very specific antagonism to PAR-2 at the cleavage site not occurring on the other member of its family. The intracellular calcium mobilization levels are indicative for a signal pathway activation of GPCRs including PAR-2.

In this case, we implemented a fluorescence-based assay for higher sensitivity at measuring intracellular calcium levels, using ow cytometry and measured the airway smooth muscle contraction in animal models.
Figure 8. PI3K Changes on Human-Derived Eosinophils from Asthmatic and Non-asthmatic Participants. A. We observed a significant decrease of $P=0.01$ when the eosinophils of the asthmatic group were exposed to the PAR-2 antagonist. These cells showed lower inactivation for the PI3K marker. B. There was not a significant difference ($P=0.6465$) between the studied groups when exposed to the PAR-2 antagonist suggesting that the tested cells were expressing (Activated) PI3K marker at the same level. C. There was not a significant difference ($P=0.6897$) between the case-control groups upon exposure to the PAR-2 antagonist indicating that at that time PI3K marker was not detected.

Figure 9. MAPK Changes on Human-Derived Eosinophils from Asthmatic and Non-asthmatic Participants. A. There was not a significant difference ($P=0.1291$) between the asthmatic and non-asthmatic groups when exposed to the PAR-2 antagonist, showing that the cells were not activated (Inactivated) for the MAPK marker at that time point. B. There was not a significant difference ($P=0.5180$) between the studied group when exposed to the PAR-2 antagonist indicating that cells were expressing (Activated) MAPK marker at the same level. C. There was not a significant difference ($P=0.7769$) between the eosinophils derived from asthmatic and non-asthmatic, when exposed to the PAR-2 antagonist on cells lacking expression (Non-Expressed) of the MAPK marker.
the quantification. Since the PAR-2 cleavage site is located at the extracellular cytoplasmic region, once cleaved it is rapidly autoactivated and the signal transduction is triggered at a time frame from 0 to 180 seconds in our case the optimal time was 45 second for data recording.

All 3 human lung primary cells (the bronchial/tracheal epithelial cells, human small airway epithelial cells and bronchial smooth muscle cells) showed a significant increase on intracellular calcium levels mobilization representative of the PAR-2 activation. We observed the opposite outcomes when the cells were exposed to the PAR-2 antagonist; the levels of intracellular calcium were significantly lower as reduced in a blocked activation. Guided by our results, we were able to find a commercially available asthmatic-derived eosinophils, or an upregulation of PAR-2 in asthmatic suggesting a PAR-2 hypersensitivity of asthmatic-derived eosinophils compared to the non-asthmatic group. This finding may be attributed to the treatment concentration. There were no significant differences within the groups of eosinophils upon exposure to the PAR-2 antagonist FSLLRY-NH2 antagonist block the signal transduction, which is implicated in the recruitment of eosinophils. For instance, at this situation circulatory eosinophils will not be considered as a therapeutic target. Our results indicated the potential of this molecule for fast track studies from translational to clinical settings, even more that PAR-2 antagonist FSLLRY-NH2 can be developed as a nebulizer or aerosolized formulation and used as an adjuvant therapy for treatment and managing of asthma. The effect of PAR-2 identified in this study provides the opportunity to perform further studies with this puzzling GPCR signaling.

Acknowledgments

Special thanks to: Ponce Health Sciences University Staff, PHSU MD student Joedali Baez and undergrad Students from the University of Puerto Rico at Ponce, Emmanuel Leon-Colon, Gerardo Arroyo, Solymar Feliciano, Nicole de la Rosa, and Maryangie Martinez for technical assistance. Luisa Morales, Dr.P.H. for revision and determination of the statistical analyses.

Author contributions

Conceptualization: Marinel Ocasio-Rivera, Frances Marin-Maldonado, Angely Ortiz-Rosado, Sharilyn Almodovar, Edu B Suarez-Martinez.

Data curation: Marinel Ocasio-Rivera, Frances Marin-Maldonado, Geraline Trossi-Torres, Angely Ortiz-Rosado.

Formal analysis: Marinel Ocasio-Rivera, Frances Marin-Maldonado, Geraline Trossi-Torres, Valerie Rodriguez-Irizarry, Edu B Suarez-Martinez.

Funding acquisition: Edu B Suarez-Martinez.

Investigation: Marinel Ocasio-Rivera, Frances Marin-Maldonado, Angely Ortiz-Rosado, Valerie Rodriguez-Irizarry.

Methodology: Marinel Ocasio-Rivera, Frances Marin-Maldonado, Geraline Trossi-Torres, Angely Ortiz-Rosado, Valerie Rodriguez-Irizarry, Eric Rodriguez-Lopez, Edu B Suarez-Martinez.

Project administration: Frances Marin-Maldonado, Geraline Trossi-Torres, Angely Ortiz-Rosado, Eric Rodriguez-Lopez, Edu B Suarez-Martinez.

Resources: Edu B Suarez-Martinez.

Software: Marinel Ocasio-Rivera, Frances Marin-Maldonado, Geraline Trossi-Torres, Angely Ortiz-Rosado, Valerie Rodriguez-Irizarry, Eric Rodriguez-Lopez.

Supervision: Frances Marin-Maldonado, Geraline Trossi-Torres, Edu B Suarez-Martinez.

Validation: Edu B Suarez-Martinez.

Visualization: Edu B Suarez-Martinez.

Writing – original draft: Marinel Ocasio-Rivera.

Writing – review & editing: Sharilyn Almodovar, Edu B Suarez-Martinez.

References

[1] NHLBI. Asthma. National Institutes of Health. 2014:https://www.nhlbi.nih.gov/health-topics/asthma.
[2] Burchard EG, Avila PC, Nazario S, et al. Lower bronchodilator responsiveness in Puerto Rican than in Mexican subjects with asthma. Am J Respir Crit Care Med 2004;169:386–92.

[3] Montalegre F, Bayona M. An estimate of the prevalence, severity and seasonality of asthma in visitors to a Ponce shopping center. P R Health Sci J 1996;15:113–7.

[4] Bolton SJ, McNulty CA, Thomas RJ, et al. Expression of and functional responses to protease-activated receptors on human eosinophils. J Leukoc Biol 2003;74:60–8.

[5] Uehara A, Muramoto K, Takada H, et al. Neutrophil serine proteinases activate human non-epithelial cells to produce inflammatory cytokines through protease-activated receptor 2. J Immunol 2003;170:5690–6.

[6] Ubl JJ, Grishina ZV, Sukhomlin TK, et al. Human bronchial epithelial cells express PAR-2 with different sensitivity to thermolysin. Am J Physiol Lung Cell Mol Physiol 2002;282:L1339–48.

[7] Berger P, Perng DW, Thabrew H, et al. Tryptase and agonists of PAR-2 induce the proliferation of human airway smooth muscle cells. J Appl Physiol (1985) 2001;91:1369–78.

[8] Chambers LS, Black JL, Poronnik P, et al. Functional effects of protease-activated receptor-2 stimulation on human airway smooth muscle. Am J Physiol Lung Cell Mol Physiol 2001;281:L1369–81.

[9] D’Andrea MR, Rogahn CJ, Andrade-Gordon P. Localization of protease-activated receptors-1 and -2 in human mast cells: indications for an amplified mast cell degranulation cascade. Biotech Histochem 2000;75:85–90.

[10] Schmidlin F, Amadesi S, Dabbagh K, et al. Protease-activated receptor 2 mediates eosinophil infiltration and hyperreactivity in allergic inflammation of the airway. J Immunol 2001;167:5315–21.

[11] Rucciardolo FL, Stendoff M, Amadesi S, et al. Presence and bronchomotor activity of protease-activated receptor-2 in guinea pig airways. Am J Respir Crit Care Med 2000;161:1672–80.

[12] Ososkovaya VS, Bunnert NW. Protease-activated receptors: contribution to physiology and disease. Physiol Rev 2004;84:579–621.

[13] Heuberger DM, Schuepbach RA. Protease-activated receptors (PARs): mechanisms of action and potential therapeutic modulators in PAR-driven inflammatory diseases. Thromb J 2019;17:4.

[14] Ge S, Li T, Yao Q, et al. Expression of protease-activated receptor (PAR)-2 in monocytes from allergic patients and potential molecular mechanism. Cell Biol Toxixol 2016;32:529–42.

[15] Hgrass MM, Kamel FO. Effect of Protease-Activated Receptor-2-Activating Peptide on Guinea Pig Airway Resistance and Isolated Tracheal Strips. J Microsc Ultrastruct 2020;87:7–13.

[16] Nadeem A, Alharbi NO, Vlahogefs H, et al. Proteinase activated receptor-2-mediated dual oxidase-2 up-regulation is involved in enhanced airway reactivity and inflammation in a mouse model of allergic asthma. Immunology 2015;145:391–403.

[17] Knight DA, Lim S, Saffadi AK, et al. Protease-activated receptors in human airways: upregulation of PAR-2 in respiratory epithelium from patients with asthma. J Allergy Clin Immunol 2001;108:797–803.

[18] Aubier M, Thabut G, Hamidi F, et al. Airway smooth muscle enlargement is associated with protease-activated receptor 2 ligand overexpression in patients with difficult-to-control severe asthma. J Allergy Clin Immunol 2016;138:729–39, e711.

[19] Martinez E. Protease Activated Receptor-2 and Gastrointestinal Dysfunction in Critical Illness. Accessed August 2020.

[20] Sherwood CL, Daines MO, Price TJ, et al. A highly potent agonist to protease-activated receptor-2 reveals apical activation of the airway epithelium resulting in Ca2+-regulated ion conductance. Am J Physiol Cell Physiol 2014;307:C718–726.

[21] Yau MK, Suen JY, Xu W, et al. Potent Small Agonists of Protease Activated Receptor 2. ACS Med Chem Lett 2016;7:105–10.

[22] Wilson S, Greer B, Hooper J, et al. The membrane-anchored serine protease, TMPRSS2, activates PAR-2 in prostate cancer cells. Biochem J 2005;388:967–72.

[23] Suarez-Martinez EB. Allelic Frequency of PAR-2 in the Puerto Rican population: a possible insight to asthma prevalence. Ceiba. 2007.

[24] Mike S, Kita H. Human eosinophils are activated by cysteine proteases and release inflammatory mediators. J Allergy Clin Immunol 2003;111:704–13.

[25] Cottrell GS, Amadesi S, Schmidlin F, et al. Protease-activated receptor 2: activation, signalling and function. Biochem Soc Trans 2003;31:1191–7.

[26] Sun Z, Cao B, Wu J. Protease-activated receptor 2 enhances renal cell carcinoma cell invasion and migration via PI3K/AKT signaling pathway. Exp Mol Pathol 2015;98:382–9.

[27] Aubier M, Thabut G, Hamidi F, et al. Airway smooth muscle enlargement is associated with protease-activated receptor 2 ligand overexpression in patients with difficult-to-control severe asthma. J Allergy Clin Immunol 2001;108:797–803.

[28] Aubier M, Thabut G, Hamidi F, et al. Airway smooth muscle enlargement is associated with protease-activated receptor 2 ligand overexpression in patients with difficult-to-control severe asthma. J Allergy Clin Immunol 2001;108:797–803.